ReviewPost ScreenSynthetic therapeutic peptides: science and market
Section snippets
Recent pharmaceutical market evolution
The pharmaceutical market is evolving in a context of increasing economic pressure. First, public authorities are pushing for lower healthcare costs through reduced drug pricing and increasing use of generic substitution. Second, regulatory authorities are more demanding in terms of drug efficacy, quality and safety, which – combined with (bio)technological progress – has led to an increase in pharmaceutical R&D costs [1]. At the beginning of the 2000s, the Tufts Center for the Study of Drug
Peptide limitations
Bioavailability and biodistribution of peptide drug candidates, which include absorption, transport, passage of biological membranes and cellular barriers, are determined by a combination of their physicochemical properties, such as aqueous solubility, lipophilicity, H-bond formation, chemical stability and metabolic stability (proteolytic and/or enzymatic degradation). With a few exceptions, peptides composed of natural amino acids are not very good drug candidates because of their intrinsic
Chemical strategies to improve peptide biological activity, specificity and stability
As discussed previously, the low bioavailability of peptides is due in part to high biodegradability by gastrointestinal, plasma and tissue peptidases. Moreover, their rapid removal from the circulation can also limit their therapeutic use. Absorption, distribution, metabolism and excretion processes play a pivotal part in defining the disposition of a drug candidate and, thus, its therapeutic effect [25]. To develop a peptide as a therapeutic agent, its biological effect, pharmacokinetic
Advantages of peptides over other drug candidates
Compared with proteins and antibodies, peptides have the potential to penetrate further into tissues owing to their smaller size. Moreover, therapeutic peptides, even synthetic ones, are generally less immunogenic than recombinant proteins and antibodies [35]. Peptides have other advantages over proteins and antibodies as drug candidates, including lower manufacturing costs (synthetic versus recombinant production), higher activity per unit mass (15–60-fold, assuming 75 kDa for one combining
Market for synthetic therapeutic peptides
The market for synthetic therapeutic peptides rose from €5.3 billion in 2003 to €8 billion in 2005. It has been estimated that it will reach €11.5 billion in 2013 [16]. This excludes peptides, proteins and antibodies extracted from natural sources or produced by recombinant DNA technology, cell-free expression systems, transgenic animals and plants and enzyme technology.
As described in Table 2, more than 60 synthetic therapeutic peptides (comprising those used for medical diagnostics or
Concluding remarks
As stated by Loffet [34], peptides (or proteins) still suffer from a deficit in image because they (generally) have to be injected, but erythropoietin and insulin are blockbusters even though they cannot be taken orally. We are convinced that chronic treatment with new formulations or routes of administration will give a new impetus to the therapeutic peptide field [52]. The majority of marketed peptide products and homologous compounds (proteins and antibodies) are peptide hormones or peptide
References (55)
- et al.
Is declining innovation in the pharmaceutical industry a myth?
Drug Discov. Today
(2005) The price of innovation: new estimates of drug development costs
J. Health Econ.
(2003)Therapeutic peptides: technological advances driving peptides into development
Curr. Opin. Biotechnol.
(2006)Prodrugs for improved CNS delivery
Adv. Drug Deliv. Rev.
(1996)- et al.
The development of site-specific drug-delivery systems for protein and peptide biopharmaceuticals
Trends Biotechnol.
(1998) - et al.
Medicinal chemical properties of successful central nervous system drugs
NeuroRx
(2005) Phage display-derived peptides as therapeutic alternatives to antibodies
Drug Discov. Today
(2004)Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
Adv. Drug Deliv. Rev.
(1997)Drug-like properties and the causes of poor solubility and poor permeability
J. Pharmacol. Toxicol. Methods
(2000)Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
Adv. Drug Deliv. Rev.
(2001)
Lead- and drug-like compounds: the rule-of-five revolution
Drug Discov. Today Technol.
Pharmaceutical profiling in drug discovery
Drug Discov. Today
Discovering and improving novel peptide therapeutics
Curr. Opin. Pharmacol.
Therapeutic peptides
Trends Biotechnol.
Transporter-mediated permeation of drugs across the blood–brain barrier
J. Pharm. Sci.
The use of cell-penetrating peptides for drug delivery
Drug Discov. Today
Approved antibodies for imaging and therapeutic: an update
IBS
Therapeutic application of peptides and proteins: parenteral for ever?
Trends Biotechnol.
Research advances in the development of peptide antibiotics
J. Pharm. Sci.
Cutting the cost of drug development?
Nat. Rev. Drug Discov.
The cost of biopharmaceutical R&D: is biotech different?
Manag. Decis. Econ.
Can the pharmaceutical industry reduce attrition rates?
Nat. Rev. Drug Discov.
Drug development for CNS disorders: strategies for balancing risk and reducing attrition
Nat. Rev. Drug Discov.
2007 FDA drug approvals: a year of flux
Nat. Rev. Drug Discov.
2008 FDA drug approvals: a year of flux
Nat. Rev. Drug Discov.
Watching peptide drugs grow up
Chem. Eng. News
Therapeutic peptides revisited
Nat. Biotechnol.
Cited by (1222)
Therapeutic stapled peptides: Efficacy and molecular targets
2024, Pharmacological ResearchPreparation and optimization of agarose or polyacrylamide/amino acid-based double network hydrogels for photocontrolled drug release
2024, International Journal of Biological MacromoleculesAmphiphilic small molecule antimicrobials: From cationic antimicrobial peptides (CAMPs) to mechanism-related, structurally-diverse antimicrobials
2023, European Journal of Medicinal ChemistryEncapsulation in oleyl-modified hyaluronic acid nanogels substantially improves the clinical potential of the antimicrobial peptides SAAP-148 and Ab-Cath
2023, European Journal of Pharmaceutics and Biopharmaceutics